Preprint Review Version 2 Preserved in Portico This version is not peer-reviewed

Monitoring Antibiotics and Inflammatory Markers in Human Blood: Impact in Choice of Antibiotic Therapy and Used Methods

Version 1 : Received: 13 November 2019 / Approved: 14 November 2019 / Online: 14 November 2019 (11:27:55 CET)
Version 2 : Received: 16 December 2019 / Approved: 16 December 2019 / Online: 16 December 2019 (11:25:16 CET)

How to cite: Berlina, A.N.; Zherdev, A.V.; Dzantiev, B.B. Monitoring Antibiotics and Inflammatory Markers in Human Blood: Impact in Choice of Antibiotic Therapy and Used Methods. Preprints 2019, 2019110163 (doi: 10.20944/preprints201911.0163.v2). Berlina, A.N.; Zherdev, A.V.; Dzantiev, B.B. Monitoring Antibiotics and Inflammatory Markers in Human Blood: Impact in Choice of Antibiotic Therapy and Used Methods. Preprints 2019, 2019110163 (doi: 10.20944/preprints201911.0163.v2).

Abstract

In the modern world, the problem of antibiotic therapy is acute. Despite the diversity of existing antibiotic drugs, their efficacy decreases as new, resistant forms of pathogenic microorganisms emerge. It is extremely difficult to control such processes and even more difficult to treat severe bacterial infections. In such situations, an individual approach to each patient is required and physicians need parameters to estimate the efficacy of antibiotic therapy. This review discusses the significance of monitoring the content of antibiotics in the blood for this purpose, in combination with the content of inflammatory markers, such as C-reactive protein and procalcitonin. The basic principles of antibiotic therapy, and factors in the resistance of microorganisms to antibiotics, are examined. Approaches to assess the efficacy of antibiotic therapy, as well as methods to detect antibiotics and inflammatory markers in the blood of patients, and comparative assessment of their capabilities and limitations, are described.

Subject Areas

individual therapy; metabolism of antibiotics; dosage choice; inflammation; biomarkers

Comments (1)

Comment 1
Received: 16 December 2019
Commenter: Boris Dzantiev
Commenter's Conflict of Interests: Author
Comment: We have received the comment on our review: "I was reviewing this article given the noted information for omadacycline. In my reading I noticed that within Table 5 the Cmin for omadacycline is incorrectly listed as 16.0 +/- 3.5 this is the half-life which it is appropriately noted in the next column. The Cmin should be listed as 0.28 +/- 0.10 as per the reference used Gotfried et al. 2017. Antimicrob Agents Chemother 61:e01135-17. https://doi.org/10.1128/AAC.01135-17. Lastly Table 6 appears to be inappropriately named as ". Pharmacokinetic parameters for omadacycline and tigecycline in plasma, administered intravenously for 30 min, at doses of 100 mg and 50 mg, respectively" which is the name of Table 5". In accordance to the comment of the reviewer, we changed the title of Table 6 and changed the Cmin of omadacycline in Table 5.
+ Respond to this comment

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 1
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.